TY - JOUR
T1 - Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg
T2 - Outcome of the patients alive after a 6-year follow-up
AU - Palandri, Francesca
AU - Castagnetti, Fausto
AU - Testoni, Nicoletta
AU - Luatti, Simona
AU - Marzocchi, Giulia
AU - Bassi, Simona
AU - Breccia, Massimo
AU - Alimena, Giuliana
AU - Pungolino, Ester
AU - Rege-Cambrin, Giovanna
AU - Varaldo, Riccardo
AU - Miglino, Maurizio
AU - Specchia, Giorgina
AU - Zuffa, Eliana
AU - Ferrara, Felicetto
AU - Bocchia, Monica
AU - Saglio, Giuseppe
AU - Pane, Fabrizio
AU - Alberti, Daniele
AU - Martinelli, Giovanni
AU - Baccarani, Michele
AU - Rosti, Gianantonio
PY - 2008/12
Y1 - 2008/12
N2 - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as
AB - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as
KW - Blast crisis
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Long-term
KW - Outcome
UR - http://www.scopus.com/inward/record.url?scp=57349124075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57349124075&partnerID=8YFLogxK
U2 - 10.3324/haematol.13068
DO - 10.3324/haematol.13068
M3 - Article
C2 - 18838477
AN - SCOPUS:57349124075
VL - 93
SP - 1792
EP - 1796
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 12
ER -